Table 1.
Characteristics of Participants Overall and by Sex
| Characteristics | No. of Samples (%) (n = 84 Samples; N = 16 Participants) | ||
|---|---|---|---|
| Longitudinal Cohort | |||
| Days post symptom onset (IQR) | 13 (10–16) | ||
| Euroimmun anti-spike IgG | |||
| Seropositive | 64 (76) | ||
| Indeterminate | 1 (1) | ||
| Seronegative | 19 (23) | ||
| EDI anti-nucleocapsid IgG | |||
| Seropositive | 75 (89) | ||
| Indeterminate | 2 (2) | ||
| Seronegative | 7 (8) | ||
| Convalescent Plasma Cohort | |||
| No. of participants (%) | |||
| Overall (n = 130) | Female (n = 60) | Male (n = 70) | |
| Age group, y | |||
| 18–29 | 34 (26) | 17 (28) | 17 (24) |
| 30–39 | 23 (18) | 9 (15) | 14 (20) |
| 40–49 | 28 (22) | 13 (22) | 15 (21) |
| 50–59 | 23 (18) | 11 (18) | 12 (17) |
| ≥60 | 22 (17) | 10 (17) | 12 (17) |
| Race/ethnicity | |||
| Non-Hispanic white | 98 (75) | 47 (78) | 51 (73) |
| Non-Hispanic black | 4 (3) | 2 (3) | 2 (3) |
| Hispanic | 5 (4) | 4 (7) | 1 (1) |
| Non-Hispanic Asian | 14 (11) | 2 (3) | 12 (17) |
| Other/multiracial/unknown | 9 (7) | 5 (8) | 4 (6) |
| Median days post symptom onset (IQR)a | 49 (43–55) | 50 (43–56) | 48 (43–54) |
| Hospitalization status severity | |||
| No | 117 (90) | 52 (87) | 65 (93) |
| Yes | 11 (8) | 6 (10) | 5 (7) |
| Missing | 2 (2) | 2 (3) | 0 (0.0) |
| Euroimmun anti-spike IgG | |||
| Seropositive | 117 (90) | 50 (83) | 67 (96) |
| Indeterminate | 7 (5) | 5 (8) | 2 (3) |
| Seronegative | 5 (4) | 4 (7) | 1 (1) |
| Missing | 1 (1) | 1 (2) | 0 (0) |
| EDI anti-nucleocapsid IgG | |||
| Seropositive | 105 (81) | 46 (77) | 59 (84) |
| Indeterminate | 9 (7) | 5 (8) | 4 (6) |
| Seronegative | 16 (12) | 9 (15) | 7 (10) |
Abbreviations: EDI, Epitope Diagnostics Inc.; IgG, immunoglobulin G; IQR, interquartile range.
aData were missing for 1 participant.